Company intelligence / Profile preview

Zfuze

Austin, Texas, United States

Ownership: Private
Development stage: Other

Overview

ZFUZE achieved FDA clearance in November 2019 for spinal fusion devices. A 75-patient retrospective study demonstrated a 93.4% lumbar spinal fusion rate at 6 months, significantly outperforming competitive studies showing average fusion rates of 68% at 12 months. As of late 2020, ZFUZE had been used in more than 100 patients.

Therapeutic areas: OtherRheumatology
Modalities: Biomaterial
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Zfuze.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zfuze.

Explore the full profile